Skip to content
DataLookout
Menu

NCT04824144

Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care

StatusCompleted
PhasePhase 1/2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Sep 6, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial status changed: Unknown → Completed
    • Final enrollment: 11 participants (planned 50)
    • Primary completion date changed from estimate of Jan 31, 2026 to Jan 27, 2025
    • Start date moved earlier from Jan 30, 2024 to Sep 8, 2022
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Primary completion date: Jan 30, 2025 to Jan 31, 2026
    • Trial status: Recruiting to Unknown
    • Study completion date: Mar 30, 2025 to Mar 31, 2026
    v7
  4. Minor Primary completion date: Nov 30, 2024 to Jan 30, 2025
    • Study completion date: Nov 30, 2024 to Mar 30, 2025
    • Start date changed from estimate of Nov 14, 2023 to Jan 30, 2024
    • Site details revised at 1 of 3 sites
    v6
  5. Notable Primary and study completion dates pushed to Nov 30, 2024v5 Show 5 more changesShow less
    • Start date: Jun 13, 2022 to Nov 14, 2023
    • Eligibility criteria expanded, about 52 words
    • Study sites: 4 to 3
    • Study description expanded, about 61 words
    • Collaborators: 4 to 3
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 5 more changesShow less
    • Primary completion date: Nov 2022 to Oct 2023
    • Start date changed from estimate of Dec 2021 to Jun 13, 2022
    • Study sites: 0 to 4
    • Study completion date: Dec 2022 to Nov 2023
    • Collaborators: 5 to 4
  2. Notable Start date: Oct 2021 to Dec 2021
    • Primary completion date: Sep 2022 to Nov 2022
    • Study completion date: Oct 2022 to Dec 2022
    v3
  3. Notable Lead sponsor: Ottawa Hospital Research Institute to Bruyère Health Research Institute.v2 Show 5 more changesShow less
    • Start date: Jul 2021 to Oct 2021
    • Primary completion date: Jun 2022 to Sep 2022
    • Study completion date: Sep 2022 to Oct 2022
    • Secondary endpoints: details revised at 2 of 4 entries
    • Collaborators: 6 to 5
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dosing - Therapeutic Dose
Timeframe: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Dosing - Time
Timeframe: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Number of Participants With Adverse Events - Bradycardia
Timeframe: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Number of Participants With Adverse Events - Hypotension
Timeframe: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Number of Participants With Adverse Events - Skin Tolerability
Timeframe: Enrollment to study withdrawal, hospital discharge, or death, whichever is first
Recruitment Rate
Timeframe: Through study completion, up to 1 year
Cost
Timeframe: Through study completion, up to 13 months
Baseline Agitation
Timeframe: Baseline
Baseline Delirium Severity
Timeframe: Baseline
Change in Agitation
Timeframe: Measured at Day 1 - 1 hour post administration, one hour post any dose change, and once daily from Day 1 to intervention completion (up to 13 months)
Change in Delirium Severity
Timeframe: Measured every 8 hours from Day 1 to intervention completion (up to 13 months)

Secondary (4)

Baseline Pain
Change in Pain From Baseline
Baseline Opioid Use
Change in Opioid Use From Baseline

Arms and interventions

Dexmedetomidine subcutaneous continuous infusionExperimental

Participants will be given a starting low dose of 0.4 mcg/kg/hr, to be titrated up to a medium dose of 0.7 mcg/kg/hr and potentially up to a maximum dose of 1.0 mcg/kg/hr by subcutaneous infusion until the target RASS-PAL level has been achieved.

Drugs: Dexmedetomidine Hydrochloride

Sites

3 sites in 1 country